E
Elena Tsourdi
Researcher at Dresden University of Technology
Publications - 68
Citations - 1659
Elena Tsourdi is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Osteoporosis & Bone remodeling. The author has an hindex of 15, co-authored 48 publications receiving 1030 citations. Previous affiliations of Elena Tsourdi include German Cancer Research Center & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Elena Tsourdi,Bente L. Langdahl,Martine Cohen-Solal,Bérengère Aubry-Rozier,Erik Fink Eriksen,Núria Guañabens,Barbara Obermayer-Pietsch,Stuart H. Ralston,Richard Eastell,M. Carola Zillikens +9 more
TL;DR: There appears to be an increased risk of multiple vertebral fractures after discontinuation of denosumab although strong evidence for such an effect and for measures to prevent the occurring bone loss is lacking.
Journal ArticleDOI
Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts
Johannes Keller,Philip Catala-Lehnen,Antje K. Huebner,Anke Jeschke,Timo Heckt,Anja Lueth,Matthias Krause,Till Koehne,Joachim Albers,Jochen Schulze,Sarah Schilling,Michael Haberland,Hannah Denninger,Mona Neven,Irm Hermans-Borgmeyer,Thomas Streichert,Stefan Breer,Florian Barvencik,Bodo Levkau,Birgit Rathkolb,Eckhard Wolf,Julia Calzada-Wack,Frauke Neff,Valerie Gailus-Durner,Helmut Fuchs,Martin Hrabĕ de Angelis,Susanne Klutmann,Elena Tsourdi,Lorenz C. Hofbauer,Burkhard Kleuser,Jerold Chun,Thorsten Schinke,Michael Amling +32 more
TL;DR: It is shown that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation, and it is confirmed that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.
Journal ArticleDOI
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi,M. Carola Zillikens,Christian Meier,Jean-Jacques Body,Elena Gonzalez Rodriguez,Athanasios D. Anastasilakis,Bo Abrahamsen,Bo Abrahamsen,Eugene V. McCloskey,Lorenz C. Hofbauer,Núria Guañabens,Barbara Obermayer-Pietsch,Stuart H. Ralston,Richard Eastell,Jessica Pepe,Andrea Palermo,Bente L. Langdahl +16 more
TL;DR: An updated systematic review of existing literature on changes of bone turnover, bone mineral density, and fracture risk after denosumab discontinuation provided advice on management based on expert opinion and indicated partial efficacy of subsequent antiresorptive treatment with results seemingly dependent on duration of denosUMab treatment.
Journal ArticleDOI
Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites
Graeme Eisenhofer,Aleksander Prejbisz,Mirko Peitzsch,Christina Pamporaki,Jimmy Masjkur,Natalie Rogowski-Lehmann,Katharina Langton,Elena Tsourdi,Mariola Pęczkowska,Stephanie M. J. Fliedner,Timo Deutschbein,Felix Megerle,Henri J L M Timmers,Richard O. Sinnott,Felix Beuschlein,Martin Fassnacht,Andrzej Januszewicz,Jacques W.M. Lenders,Jacques W.M. Lenders +18 more
TL;DR: The plasma panel offers better diagnostic performance than either urinary panel for patients at high risk of disease and, with appropriate preanalytics, provides the test of choice.
Journal ArticleDOI
Selective glucocorticoid receptor modulation maintains bone mineral density in mice
Sylvia Thiele,Nicole Ziegler,Elena Tsourdi,Karolien De Bosscher,Jan Tuckermann,Lorenz C. Hofbauer,Martina Rauner +6 more
TL;DR: This study underlines the bone‐sparing potential of CpdA and suggests that by preventing increases in the RANKL/OPG ratio or DKK‐1 in osteoblast lineage cells, GC‐induced bone loss may be ameliorated.